Skip to main content

Table 1 Baseline characteristics

From: Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V

Characteristic

Edoxaban 30 mg QD (n = 255)

Enoxaparin 2000 IU BID (n = 248)

Sex

  

 Female

220 (86.3)

212 (85.5)

Age (y)

  

 Mean ± SD

62.8 ± 9.61

62.8 ± 9.72

 <75

220 (86.3)

217 (87.5)

 ≥75

35 (13.7)

31 (12.5)

Weight (kg)

  

 Mean ± SD

57.7 ± 9.72

57.0 ± 9.60

 <60

160 (62.7)

157 (63.3)

 ≥60

95 (37.3)

91 (36.7)

BMI, mean ± SD

24.5 ± 3.52

24.2 ± 3.60

CL CR (mL/min)

  

 Mean ± SD

89.6 ± 29.58

88.9 ± 26.49

 ≥80

148 (58.0)

150 (6)

 ≥50 to <80

93 (36.5)

91 (36.7)

 <50

14 (5.5)

7 (2.8)

History of artificial joint replacement of the lower limbs

39 (15.3)

35 (14.1)

Duration from the end of surgery to the start of study treatment (h)

  

 ≥12 to <18

16 (6.3)

-

 ≥18 to ≤24

239 (93.7)

-

 ≥24 to <30

-

170 (68.5)

 ≥30 to <36

-

78 (31.5)

 Hour:minute, Mean ± SD

21:40 (1:54)

28:37 (3:00)

Physiotherapy a

  

 Intermittent pneumatic compression therapy (foot sole)

137 (53.7)

135 (54.4)

 Intermittent pneumatic compression therapy (lower legs and thigh)

120 (47.1)

114 (46.0)

 Elastic stockings

209 (82.0)

201 (81.0)

Concomitant NSAIDs

250 (98.0)

243 (98.0)

Treatment duration (days)

  

 Mean ± SD

12.5 (1.4)

12.5 (1.5)

  1. Data presented as n (%) unless otherwise stated. BID, twice daily; BMI, body mass index; CLCR, creatinine clearance; IU, international unit; NSAIDs, non-steroidal anti-inflammatory drugs; QD, once daily; SD, standard deviation
  2. aPatients could be using more than one mode of physiotherapy